Weekly Digest – September 2026 Weekly Digest – September 2026 16 September 2026: ELAHERE approved in Japan for patients with FRα-positive, platinum-resistant recurrent Ovarian cancer Takeda announced that ELAHERE has been approved in Japan for the treatment of folate receptor […]
Weekly Digest – September 2026 Weekly Digest – September 2026 03 September 2026: HUTCHMED announces licensing agreement with GSK for KRAS-EGFR antibody conjugate cancer therapy HUTCHMED announced an exclusive licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy […]
Weekly Digest – August 2026 Weekly Digest – August 2026 24 August 2026: Trodelvy expanded to 1L metastatic TNBC Across PD-L1 Status in the EU Gilead announced that the European Commission has approved Trodelvy plus Keytruda for the first-line treatment […]
Weekly Digest – August 2026 Weekly Digest – August 2026 26 August 2026: Novartis’ Pluvicto receives approval in China for a new indication Novartis announced that China’s NMPA approved a new indication for Pluvicto in combination with an androgen receptor […]
Weekly Digest – August 2026 Weekly Digest – August 2026 12 August 2026: Enhertu with Pertuzumab approved in China for 1L HER2-positive metastatic Breast cancer Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab has been approved by China’s NMPA for the […]
Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: Hengrui’s Aiweida receives NMPA approval for HER2-positive Colorectal cancer Hengrui Pharma’s HER2-targeted ADC Aiweida has been approved in China for the treatment of adults with HER2-positive colorectal […]
Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer AbbVie’s ELAHERE has been approved in Russia for the treatment of epithelial ovarian, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in the EU as […]
Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease Novartis announced that the U.S. FDA has approved Pluvicto in combination with […]
Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II or III early Breast cancer AstraZeneca Pharma India announced that the Central […]
